{"schema_version":"secwatch.filing_event.v1","accession":"0001402479-23-000002","form_type":"8-K","ticker":null,"cik":"0001402479","company_name":"MedAvail Holdings, Inc.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.770375+00:00","generated_at":"2026-06-20T13:02:31.466908+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MedAvail exits pharmacy services, cuts 75% of staff; reaffirms 2022 revenue guidance of at least $42M","bullets":["Exiting pharmacy services and SpotRx business; hired broker to sell related pharmacy assets.","Reduction in force of approximately 75% of full-time employees, effective January 18, 2023.","Expected annualized operating expense savings of $35 million to $37 million compared to full year 2022.","Reaffirms FY2022 revenue guidance of at least $42 million (90% YoY growth) and 40 net new dispensing deployments.","FY2022 pharmacy technology sales expected $1.2M-$1.4M with gross margin >45%."],"urls":{"canonical":"https://secwatch.observer/filing/0001402479-23-000002","json":"https://secwatch.observer/filing/0001402479-23-000002.json","markdown":"https://secwatch.observer/filing/0001402479-23-000002.md","text":"https://secwatch.observer/filing/0001402479-23-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402479/000140247923000002/0001402479-23-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402479/000140247923000002/medavail-20230118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:02:31.466908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fda810fc5857b3f4145f477a36ac0b694f288d98","claim":"MedAvail Holdings, Inc. updated its 2022 guidance (reaffirmed).","evidence_excerpt":"On January 19, 2023, MedAvail Holdings, Inc. (the “Company”) reaffirmed guidance and announced certain preliminary estimates of selected financial results for 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402479/000140247923000002/0001402479-23-000002-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"483a8b896d8edf379102bec62073d0ee8963e726","claim":"MedAvail Holdings, Inc. announced a restructuring affecting Pharmacy Services Business (approximately 75% of the Company’s full-time employees).","evidence_excerpt":"On January 18, 2023, and in connection with the Company's exit from the Pharmacy Services Business to focus on the Pharmacy Technology Business, the Company initiated a reduction in force (the “Reduction”), in which approximately 75% of the Company’s full-time employees were immediately terminated, effective January 18, 2023","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402479/000140247923000002/0001402479-23-000002-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Affected area","value":"Pharmacy Services Business"},{"label":"Headcount","value":"approximately 75% of the Company’s full-time employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}